Clinical trial · Observational
Epidemiology Study in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer
An Epidemiological, Non-interventional Study to Evaluate Patient Compliance in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This observational study in estrogen receptor positive early breast cancer patients is aimed to evaluate the patients' compliance to aromatase inhibitor (AI) therapy and to collect country-specific data in estrogen receptor positive early breast cancer patients including data on demography, disease characteristics and disease management.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hormon Receptor Positive Breast Cancer | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- 1
- description
- Women with estrogen receptor positive breast cancer already receiving treatment with an aromatase inhibitor (AI) will be enrolled in the study
Primary outcomes (1)
- measure
- Evaluate compliance rate, as assessed by investigator, after 12 months from baseline.
- timeFrame
- 12 months
Secondary outcomes (6)
- measure
- Evaluate compliance rate, assessed by investigator, after 6 months of follow up
- timeFrame
- 12 months
- measure
- Evaluate the extent of patient educational activities as assessed by patient (using patient questionnaire) after 6 and 12 months
- timeFrame
- 12 months
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Postmenopausal females with estrogen receptor positive breast cancer that are currently treated with aromatase inhibitor (AI) medication * Provision of subject informed consent Exclusion Criteria: * If participating in any clinical trial, the subject cannot take part in this study.
References
Publications (0)
Data not yet available